TABLE 2.
Prevalence of pain and itch in diabetes in different areas, assessment methods in different studies.
| Patients and area | Number of diabetic patients | Prevalence (%) | Methods | Reference |
|---|---|---|---|---|
| Pain | ||||
| Patients with diabetes in northwest England | n = 15,692 | 21 | Questionnaire (NSS and NDS) | Abbott et al. (2011) |
| Patients with diabetes in France nationwide | n = 766 | 20.3 | Questionnaire (DN4 and MNSI), monofilament test | Bouhassira et al. (2013) |
| Patients with diabetes in United Kingdom | n = 350 | 16.2 | Questionnaire (VAS and McGill Pain) and examination | Daousi et al. (2004) |
| Patients with diabetes in Italy | n = 816 | 13 | Clinical examination and diagnostic tests | Truini et al. (2018) |
| Patients with T2DM in Denmark | n = 5,114 | 10 | Questionnaire (DN4 and MNSIq) | Gylfadottir et al. (2020) |
| Itch | ||||
| Patients with diabetes in the United Kingdom | n = 300 | 18.4 | Interviewed and clinical examination | Neilly et al. (1986) |
| Diabetic outpatients in Japan | n = 2,656 | 26.3 | Questionnaire | Yamaoka et al. (2010) |
| Patients with T2DM in Taiwan, China | n = 385 | 27.5 | Questionnaire | Ko et al. (2013) |
| Children with T1DM in Poland | n = 100 | 22 | NRS and Questionnaire (4IIQ) | Stefaniak et al. (2020) |
| Patients with T2DM in Poland | n = 109 | 35.8 | NRS and Questionnaire (4IIQ) | Stefaniak et al. (2021b) |
DN4, Diabetic Neuropathy 4; NDS, neuropathy disability score; NSS, neuropathy symptom score; MNSI, Michigan Neuropathy Screening Instrument; VAS, visual analog scale; 4IIQ, Four-item Itch Questionnaire; NRS, numerical rating scale.